ElectroCore (Nasdaq:ECOR) announced today that the U.S. Patent and Trademark office (USPTO) issued it a new nerve stimulation patent.
The new patent (No. 11,839,764 ) relates to a system for stimulating a nerve target in the head or neck of a patient. It covers the treatment of various disorders, such as primary headache. It’s titled “Systems and Methods for Treating a Medical Condition with an Electrical Stimulation Treatment Regimen.”
Issued today, Dec. 12, the patent relates to a system that includes downloadable software on, for example a mobile device. Its configuration allows it to control a parameter of the electrical impulses delivered by a stimulator for targeting nerves.
“We continue to grow our intellectual property portfolio,” said Joshua Lev, chief strategy officer of electroCore. “This new patent strengthens our position around systems that utilize mobile applications to control stimulators that treat various disorders such as primary headache, which may be useful as we develop our next generation application enabled products and devices.”
Rockaway, New Jersey-based ElectroCore continues to expand its patent portfolio with the latest win. In April, the company received a trio of patents relating to its non-invasive vagus nerve stimulation (nVNS) technology. Those patents generally relate to nVNS devices and methods for treating addiction and other medical conditions. This includes releasing dopamine and/or endogenous opioids in the patient’s brain.